How parathyroid hormone changes bone cell activity
Nuclear Events in PTHR1 Action on Bone
This project looks at how parathyroid hormone signals inside bone-forming cells to affect bone loss and bone building, with relevance for people with hyperparathyroidism, osteoporosis, or Albright syndrome.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11326713 on NIH RePORTER |
What this research studies
Researchers are studying the molecular steps that parathyroid hormone (PTH) uses inside osteoblasts (bone-forming cells) to turn on the gene RANKL, which leads to bone breakdown. In lab experiments they follow signaling molecules such as cAMP, PKA, salt‑inducible kinases (SIKs), protein phosphatases, and CRTC proteins as they move into the cell nucleus and work with bZip transcription factors. The team uses cell-based molecular experiments and related biological samples to map how these nuclear events control RANKL production. Findings may guide future ways to block harmful bone loss or improve bone-building treatments.
Who could benefit from this research
Good fit: People with hyperparathyroidism, osteoporosis, or Albright syndrome — especially adults — would be the most relevant candidates to contribute samples or be considered for future therapies informed by this research.
Not a fit: People without disorders of bone or parathyroid hormone regulation are unlikely to gain direct benefit from this work.
Why it matters
Potential benefit: If successful, this work could point to new targets for drugs that reduce bone loss or boost bone formation in conditions like hyperparathyroidism, osteoporosis, and Albright syndrome.
How similar studies have performed: Related approaches targeting the PTH–RANKL pathway have led to effective treatments (for example, teriparatide and RANKL inhibitors), but the specific nuclear signaling steps this project targets are still being explored.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Partridge, Nicola C — Rutgers Biomedical and Health Sciences
- Study coordinator: Partridge, Nicola C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.